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Abstract: Background: Inadequate levels of vitamin D (VTD) throughout the life cycle 
from the fetal stage to adulthood have been correlated with elevated risk for assorted health 
afflictions. The purpose of this study was to ascertain VTD status and associated 
determinants in three clinical practice populations
 living in Edmonton, Alberta, Canada -
 a 
locale with latitude of 53°30'N, where
 sun exposure from October through March is often 
inadequate to generate sufficient vitamin D. Methods: To determine VTD status, 1,433 
patients from three independent medical offices in Edmonton had levels drawn for 25(OH)D 
as part of their medical assessment between Jun 2001 and Mar 2007. The relationship 
between demographic data and lifestyle parameters with VTD status was explored. 
25(OH)D levels were categorized as follows: (1) Deficient: <40 nmol/L; (2) Insufficient 
(moderate to mild): 40 to <80 nmol/L; and (3) Adequate: 80-250 nmol/L. Any cases <25 
nmol/L were subcategorized as severely deficient for purposes of further analysis. Results: 
240 (16.75% of the total sample) of 1,433 patients were found to be VTD ‘deficient’ of 
which 48 (3.35% of the overall sample) had levels consistent with severe deficiency. 738 
(51.5% of the overall sample) had ‘insufficiency’ (moderate to mild) while only 31.75% had 
‘adequate’ 25(OH)D levels. The overall mean for 25(OH) D was 68.3 with SD=28.95. VTD 
status was significantly linked with demographic and lifestyle parameters including skin 
tone, fish consumption, milk intake, sun exposure, tanning bed use and nutritional 
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supplementation. Conclusion: A high prevalence of hypovitaminosis-D was found in three 
clinical practice populations living in Edmonton. In view of the potential health sequelae 
associated with widespread VTD inadequacy, strategies to facilitate translation of emerging 
epidemiological information into clinical intervention need to be considered in order to 
address this public health issue. A suggested VTD supplemental intake level is presented for 
consideration.
 
Keywords: Dietary supplements; epidemiology; hypovitaminosis-D; information science; 
knowledge translation; nutrition; public health; vitamin D; vitamin D deficiency; vitamin D 
insufficiency. 
 
1. Introduction 
 
Recent medical literature is replete with discussion about health benefits of vitamin D (VTD) 
sufficiency as well as risks for adverse sequelae and disease states associated with inadequate VTD 
levels (Table 1). Once thought to be primarily a determinant of bone health, it is now recognized that 
VTD is a requisite hormone involved in myriad physiological processes including immune 
modulation, genetic regulation, hormonal production, and cellular functioning throughout the life 
cycle. While ongoing research continues to explore the short and long-term sequelae of prenatal and 
pediatric VTD deficiency, several clinical studies in adults have linked hypovitaminosis-D with 
increased risk for various conditions including osteoporosis, assorted cancers, cardiovascular disease, 
diabetes and others. 
Several studies in the literature suggest widespread VTD inadequacy [1], particularly in higher 
latitudes where ultraviolet B (UVB) sunlight intensity is too weak for extended periods to induce 
sufficient VTD skin synthesis for many people. Despite the availability of this information, however, 
the potential lag or latent period between nutrient inadequacy and adverse health outcomes [2], as well 
as general inattention to clinical nutrition in medical education [3], has contributed to a low index of 
suspicion in clinical practice about hypovitaminosis-D as an etiological determinant of ill-health. This 
study was designed to determine the VTD status among three clinical practice populations in 
Edmonton, a locale in western Canada with latitude of 53°30'N – about the same latitude as Hamburg, 
Manchester, Liverpool, Dublin, Warsaw, Moscow and Leningrad – where
  sun exposure is often 
inadequate to generate sufficient vitamin D from October through March [4].
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Table 1. Examples of VTD Status and Clinical Outcomes. 
 
Disorder 
 
Study Design or Intervention 
 
Outcome 
 
Malignancy 
 
  
Colon cancer  
 
Prospective study of colon cancer risk 
based on levels of 25(OH)D [5] 
75-80% reduction in risk for colon cancer 
for levels between 67.5-102.5 nmol/L [5] 
Prostate cancer 
 
Comparison of men whose 25(OH)D levels 
were below versus above the median (62.5 
nmol/L in winter and 80nmol/L in summer) 
[6] 
Significantly increased risk of aggressive 
prostate cancer (odds ratio = 2.1) [6] 
Pancreatic cancer 
 
Dietary intake of 300-450 IU/d VTD 
compared to intake <150 IU/d [7] 
44% reduction in risk for pancreatic cancer 
[7] 
Breast cancer 
 
Pooled analysis of breast cancer risk based 
on VTD status [8] 
 
50% risk reduction for breast cancer 
between groups with high (median = 120 
nmol/L) vs. low 25(OH)D levels [8] 
Lung cancer  Higher levels of circulating 25(OH)D [9]   Improved survival in early stage lung cancer 
[9] 
All cancer incidence in 
postmenopausal 
women 
Double-blind, randomized placebo-
controlled trial: 1100 IU/d of VTD + 1,500 
mg calcium vs. placebo group [10] 
77% reduction in risk of cancer in years 2-5 
after commencing supplementation [10] 
 
    Musculoskeletal 
  
 
Rickets  
 
25(OH)D levels above 25 nmol/L [11] 
 
 
Resolution of symptoms and signs [11] 
 
 
Osteomalacia  
 
800 -2,200 IU/d VTD for up to a year [12] 
 
Resolution of pain symptoms [12] 
 
 
Osteoporosis 
 
 
25(OH)D levels above 78 nmol/L to 
maximize benefit [13] 
 
Improved bone density [13] 
 
Prevention of falls in 
elderly 
 
 
Review of RCTs and meta-analyses - 
VTD dose of ≥700 IU/d [14] 
 
Significant relationship between VTD 
supplementation and less risk of falls [14] 
 
Idiopathic back pain 
 
 
Achieving 25(OH)D levels >80 nmol/L 
[15]  
 
All deficient patients had pain resolution 
[15] 
 
Nonspecific chronic 
musculoskeletal pain 
 
Achieving VTD adequacy [16]  
 
 
67% of patients had complete resolution of 
symptoms [16] 
 
Dental - tooth loss in 
elderly  
 
400-600 IU VTD/d and calcium 1,000 
mg/d [17]  
 
50% improvement in tooth retention [17] 
  
 Autoimmune 
 
   
 
Multiple sclerosis 
 
 
Supplemental VTD of at least 400 IU/d 
[18] 
 
41% risk reduction for developing MS [18] 
 
Rheumatoid arthritis 
(RA) 
  
 
Intake of VTD each day [19] 
 
 
Greater VTD intake was inversely 
associated with risk of developing RA [19]  
 
 
Type I diabetes  
 
 
VTD supplementation for infants of 2000 
IU/d [20] 
 
78% risk reduction for developing Type I 
diabetes [20] Int. J. Environ. Res. Public Health 2009, 6          
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Table 1. Cont. 
 
   Cardiovascular  
 
  
Fatal Stroke (FS)  Correlated 25(OH)D levels with risk for 
fatal stroke [22] 
Highly significant correlation between low 
25(OH)D level and risk for FS [22] 
Hypertension Correlated  25(OH)D levels with risk for 
hypertension [23] 
Plasma 25(OH)D levels were inversely 
associated with risk of incident  hypertension 
[23] 
Cardiovascular events  25(OH)D levels <37.5 nmol/L versus 
those >37.5 nmol/L [24]  
Significantly increased risk of incident 
cardiovascular events (OR = 1.62) [24] 
Peripheral Arterial 
Disease (PAD) 
Correlated 25(OH)D levels with risk for 
PAD [25]  
Low
 25(OH)D levels are associated with a 
higher prevalence
 of PAD. The prevalence 
ratio for the lowest quartile compared to the 
highest was 1.80 [25] 
 
   Obstetric/Gynecologic  
 
 
 
 
Gestational diabetes 
 
 
Levels restored to > 80 nmol/L [26] 
 
Marked improvement of insulin sensitivity 
and insulin production [26] 
 
Birth weight  
 
 
Additional gestational VTD intake [27]  
 
Birth weight increased by 11g for each 
microgram of VTD given [27] 
 
Polycystic ovary disease 
 
VTD repletion with additional calcium 
[28]  
 
Normalized menses >50% of patients [28] 
  
 
Premenstrual syndrome 
 
 
Intake of VTD at ~706 IU per day vs. low 
intake of VTD at ~112 IU/d [29] 
 
40% reduction in symptoms [29] 
 
Pre-eclampsia (PE) 
 
 
Correlated 25(OH)D levels with risk of 
PE [30] 
 
Gestational 25(OH)D levels were inversely 
associated with risk of PE [30] 
 
 
 
   Respiratory 
   
 
Upper respiratory 
infections  
 
 
600-700 IU given as cod liver oil [31] 
(also given selenium and omega 3 fatty 
acids) 
 
50% reduction in incidence of new upper 
respiratory infections [31] 
 
 
Lower respiratory 
infections  
 
 
Children with <25nmol/L [32] 
 
11 times more likely to experience infection 
[32] 
 
Cystic Fibrosis (CF) 
 
 
VTD added to CF bronchial epithelial 
cells [33]  
 
 
Induction of cathelicidin production - 
increased antimicrobial activity against 
selected pathogens [33] 
 
Seasonal Influenza 
 
Increased levels of 25(OH)VTD [34] 
 
 
Up-regulates endogenous antibiotics of innate 
immunity [34] 
 
   Other 
    
 
All cause mortality 
 
Outcomes of grouped patients with 
25(OH)D levels < 42 versus those > 59 
over 7.7 year period [35] 
 
All cause mortality 2.08 times higher in lower 
25(OH)D groups [35] 
 
 
Aging and age-related 
disease 
 
 
VTD measurement correlated with 
leukocytic telomere length (a predictor 
for age-related disease) [36]  
 
 
 
Higher VTD levels are associated with 
markers for diminished aging and age-related 
diseases [36] 
 
Psoriasis 
 
VTD applied as topical cream [37] 
 
Plaque thickness and redness markedly 
improved [37] 
 
 
Type II diabetes 
 
 
Raising level from 25 to 75 nmol/L [38] 
 
Lower 25(OH)D significantly associated with 
higher risk of insulin resistance, metabolic 
syndrome and impaired beta cell function [38] Int. J. Environ. Res. Public Health 2009, 6          
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2. Methodology 
 
Three practicing physicians in Edmonton, Alberta, Canada with interest in clinical nutrition were 
recruited to assess VTD status in their patients. For a period of over five years between June 2001 and 
March 2007, a generalist Obstetrician/Gynecologist (MDA) collected 25(OH)D (the main circulating 
metabolite of VTD) levels on all new patients referred for obstetrical or gynecological care. During 
this same period, a primary care generalist (MDB) ordered 25(OH)D levels if VTD status was 
clinically deemed to be a potential determinant of the patient’s health problem. The third physician, a 
part-time family doctor (MDC), collected 25(OH)D levels on consecutive patients presenting for 
annual check-ups. MDB and MDC have general primary care practices with no decided focus on a 
specific patient or illness demographic. High-pressure liquid chromatography, mass spectrometry 
performed at a single core laboratory was used to determine 25(OH)D levels. 
Demographic data including patient age, sex, skin tone, body mass index (BMI), gestational status, 
and date of collection as well as lifestyle parameters including liquid milk consumption, sun exposure, 
use of tanning salons, medication use, vitamin D and fish oil supplementation, and levels of dietary 
fish intake were recorded. Skin tone categorization was derived from discussion reported in the 
medical literature relating to significant differences in VTD status as a function of skin tone [39-44]; 
First Nations skin tone was classified as an independent category as recent literature suggests that First 
Nations individuals have a high incidence of VTD deficiency [45-48].  
Cochran-Mantel-Haenszel's row mean score statistic was used to evaluate the relationship between 
25(OH)D levels and the demographic/lifestyle parameters. Significance levels were adjusted for the 
following list of potential confounders: physician, use of VTD and fish oil supplements, recent sun 
exposure, tanning bed use, and season. VTD status was categorized as follows: (1) VTD ‘deficient’: 
<40 nmol/L, (2) ‘insufficient’ (moderate to mild): 40 to <80 nmol/L, and (3) ‘adequate’: 80-250 
nmol/L. As a subcategory, any cases <25 nmol/L were considered severely deficient – a level 
repeatedly associated with the development of rickets in children from various jurisdictions [11, 49-
51]. The literature has not yet achieved consensus on a 25(OH)D level that maximizes multiple health 
outcomes as the roles of VTD in myriad physiological processes continue to be uncovered. Although 
variation exists in the definition of VTD ‘deficiency’ and ‘insufficiency’, levels were chosen to be 
consistent with other research studies to facilitate epidemiological comparison [52-54].  
Fisher’s exact test was used to investigate the relationship between severe deficiency with 
demographic and lifestyle characteristics. Statistical significance was defined as a p<0.05 for all 
analyses. All statistical analyses were performed using SAS
® Version 9.1 (SAS Institute Inc., Cary, 
NC). Ethics approval was received from the Health Research Ethics Board at the University of 
Alberta. Each patient signed a written consent to participate in the study. 
 
3. Results  
 
Although variation was found between each group, more than 60% of participants within each 
clinical practice demonstrated hypovitaminosis-D (Table 2) with 77% of MDA’s patients recording 
inadequate 25(OH)D levels. As three independent groups, the patients of doctors A, B, and C Int. J. Environ. Res. Public Health 2009, 6          
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displayed results that were significantly different from one another - with mean VTD levels in the 
patients of MDA<MDB (p<0.0001); MDB<MDC (p=0.0007) and MDA<MDC (p=0.0046). MDB had 
older patients than MDA and MDC (both adjusted p<0.001), and MDC’s patients were older than 
MDA’s (adjusted p=0.0376). A higher proportion of MDB’s patients used fish oil compared to patients 
in both other clinical practices (both adjusted p<0.0001). 
 
Table 2. VTD Status by Clinical Practice and Practice Comparison for Patient Age and 
Supplement Use. 
Clinical Practice 
 25(OH)D Level by Clinical Practice – n (%)  25(OH)D Level (nmol/L) 
<40 nmol/L  40 to <80 nmol/L  80-250 nmol/L  Mean  SD 
MDA     (n=570)  105 (18%)  335 (59%)  130 (23%)  63.02  26.86 
MDB     (n=686)  118 (17%)  309 (45%)  259 (38%)  70.76  29.13 
MDC     (n=177)  17 (10%)  94 (53%)  66 (37%)  76.02  31.76 
Overall   (n=1433)  240 (16.75%)  738 (51.5%)  455 (31.75%)  68.33  28.95 
Clinical Practice 
 Age Distribution by Clinical Practice – n (%) 
Adjusted P-
value<0.0001 
Pediatrics 
(<19 years)  
Young Adults  
(19 to 30 years)  
Middle Adults 
(30 to <60 years) 
Seniors    (60 
and older) 
MDA     (n=570)  30 (5%)  99 (17%)  369 (65%)  72 (13%)   
MDB     (n=686)  43 (6%)  56 (8%)  280 (41%)  307 (45%)   
MDC     (n=177)  14 (8%)  17 (10%)  105 (59%)  41 (23%)   
Clinical Practice 
Fish Oil Supplement Use by Clinical Practice – n (%)  Adjusted P-
value<0.0001  No  Yes 
MDA     (n=570)  483 (85%)  87 (15%)   
MDB     (n=680)  449 (66%)  231 (34%)   
MDC     (n=161)  142 (88%)  19 (12%)   
Clinical Practice 
 VTD Supplement Use by Clinical Practice – n (%) 
Missing Data  Adjusted P-
value 0.9926  None  50-400 IU  >400 IU 
MDA     (n=570)  272 (48%)  228 (40%)  70 (12%)  0   
MDB     (n=680)  374 (55%)  176 (26%)  130 (19%)  6 (<1%)   
MDC     (n=161)  68 (42%)  83 (52%)  10 (6%)  16 (9%)   
 
VTD status according to demographic characteristics of study participants is summarized in Table 
3. Darker skin with higher melanin blocks UV penetration and retards VTD synthesis. VTD status 
correlated significantly with skin tone - First Nations and dark-skinned individuals had particularly 
low 25(OH)D levels. Consistent with other reports in the literature, VTD status correlated with season 
- levels in summer and fall were higher than those in spring and winter although not significantly when 
adjusted for potential confounders.  
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Table 3. Vitamin D Status by Demographic Characteristic. 
Characteristic 
 25(OH)D Level – n (%)  Adjusted P-
value  <40 nmol/L  40 to <80 nmol/L  80-250 nmol/L 
Age       0.1996 
  Pediatric (<19 years)  24 (28%)  45 (52%)  18 (21%)   
  Young Adult (19 to < 30 years)  35 (20%)  91 (53%)  46 (27%)   
  Middle Adult (30 to < 60 years)  136 (18%)  414 (55%)  204 (27%)   
  Senior (60 and greater years)  45 (11%)  188 (45%)  187 (45%)   
Sex       0.7648 
  Male  62 (17%)  185 (50%)  123 (33%)   
  Female  178 (17%)  553 (52%)  332 (31%)   
Skin Tone        <0.0001 
  Dark  8 (44%)  6 (33%)  4 (22%)   
  Midcolor  43 (23%)  95 (51%)  47 (25%)   
  Light  173 (15%)  621 (53%)  385 (33%)   
  First Nations   16 (48%)  11 (33%)  6 (18%)   
Pregnant (Females Only)        0.8298 
  No  159 (16%)  508 (52%)  310 (32%)   
  Yes  19 (23%)  44 (53%)  20 (24%)   
BMI (n=704)        0.2959 
  Underweight (BMI≤18.5)  8 (24%)  17 (52%)  8 (24%)   
  Normal (18.5<BMI<25)  51 (16%)  181 (56%)  90 (28%)   
  Overweight (25≤BMI<30)  31 (14%)  118 (54%)  68 (31%)   
  Obese (BMI≥30)  29 (22%)  78 (59%)  25 (19%)   
Season       0.1447 
  Spring (March-May)  94 (22%)  220 (51%)  121 (28%)   
  Summer (June – August)  30 (10%)  170 (57%)  99 (33%)   
  Fall (Sept – November)  38 (12%)  163 (50%)  123 (38%)   
  Winter (December – February)  78 (21%)  185 (50%)  110 (29%)   
Note: some of the % do not add up to 100% due to rounding. 
 
Lifestyle characteristics as they relate to 25(OH)D level are presented in Table 4 and outcomes are 
consistent with findings in the literature. Fish ingestion, VTD supplementation, fish oil use, regular 
consumption of VTD fortified milk, tanning bed use, and level of sun exposure were strongly 
correlated with 25(OH)D results. With milk consumption, however, preferred levels were realized only 
with ingestion of more than two glasses per day (both adjusted p<0.001). Supplemental VTD intake of 
up to 400 IU (often the current recommended intake) had a modest effect on 25(OH)D values with 
major gains in VTD sufficiency achieved only when supplemental ingestion exceeded 400 IU per day 
(all adjusted p<0.0001). Weekly fish consumers had higher 25(OH)D levels than fish abstainers 
(adjusted p=0.0021) and periodic or regular use of tanning beds also resulted in higher VTD values Int. J. Environ. Res. Public Health 2009, 6          
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(both adjusted p<0.0001). As expected, 25(OH)D values rose with increasing sun exposure (all 
adjusted p<0.0001). Participants not using VTD or fish oil supplementation had lower mean 25(OH)D 
levels while those using tanning beds and high sun exposure had superior VTD values. (Table 5) 
 
Table 4. Vitamin D Status by Lifestyle Characteristic. 
Characteristic 
 25(OH)D Level – n (%) 
Adjusted P-
value  <40 nmol/L  40 to <80 nmol/L  80-250 nmol/L 
Glasses of Milk per day        <0.0001 
  None  151 (21%)  353 (50%)  209 (29%)   
  1-2  76 (15%)  273 (55%)  143 (29%)   
  >2  13 (6%)  107 (52%)  86 (42%)   
Fish Servings per week        0.0159 
  0  146 (20%)  400 (54%)  196 (26%)   
  1  67 (14%)  235 (51%)  163 (35%)   
  >1  26 (13%)  98 (48%)  79 (39%)   
Fish Oil Supplement        <0.0001 
  No  219 (20%)  588 (55%)  267 (25%)   
  Yes  21 (6%)  145 (43%)  171 (51%)   
Vitamin D Supplement        <0.0001 
  None  204 (29%)  394 (55%)  116 (16%)   
  50-400 IU  30 (6%)  284 (58%)  173 (36%)   
  >400 IU  6 (3%)  55 (26%)  149 (71%)   
Recent Sun Exposure       <0.0001 
  Minimal  201 (23%)  454 (52%)  223 (25%)   
  Moderate  33 (9%)  197 (54%)  132 (36%)   
  Lots of Sun  6 (4%)  82 (48%)  83 (49%)   
Tanning Bed Use        <0.0001 
  None  238 (19%)  675 (53%)  366 (29%)   
  Sometimes  2 (2%)  48 (44%)  59 (54%)   
  Regular Use (average ≥1/mos)  0 (0%)  10 (43%)  13 (57%)   
Medications       0.8423 
  None  103 (18%)  306 (54%)  154 (27%)   
  Meds not related to VTD  119 (16%)  384 (52%)  239 (32%)   
  Meds known to impact VTD   18 (16%)  43 (39%)  49 (45%)   
Note: some of the % do not add up to 100% due to rounding. 
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Table 5. Vitamin D Status by Significant Lifestyle Characteristics. 
Category 
25(OH)D Level – n (%)  25(OH)D Level (nmol/L) 
<40 nmol/L  40 to <80 nmol/L  80-250 nmol/L  Mean  SD 
 
No VTD or Fish Oil 
Supplementation (n=605) 
 
188 (31%) 
 
335 (55%) 
 
82 (14%) 
 
54.60 
 
25.15 
 
No VTD or Fish Oil 
Supplementation and No 
Servings of Fish (n=361) 
 
118 (33%) 
 
195 (54%) 
 
48 (13%) 
 
53.74 
 
24.41 
 
No VTD or Fish Oil 
Supplementation, No Fish 
Servings and Minimal Sun 
Exposure (n=231)
 
 
98 (42%) 
 
123 (53%) 
 
10 (4%) 
 
46.60 
 
19.39 
 
Tanning Bed Use (n=132) 
 
2 (1.5%) 
 
58 (44%) 
 
72 (54.5%) 
 
86.32 
 
31.59 
 
Tanning Bed Use and Lots of 
Sunlight (n=26) 
 
0 (0%) 
 
10 (38%) 
 
16 (62%) 
 
102.27 
 
42.12 
 
A small percentage of patients (48 of 1433 or 3.35%) exhibited severe VTD deficiency - i.e. 
25(OH)D values <25 nmol/L. (Table 6) Dark-skinned and First Nations individuals were most at risk 
while participants using supplemental fish oil or VTD had negligible rates of severe deficiency. 
Furthermore, milk drinkers were significantly less likely to be severely deficient than non-milk 
drinkers (p=0.0001) confirming food fortification with VTD as a potent public health measure. Only 2 
cases (<1%) of severe deficiency occurred among those with regular sun exposure compared to the 46 
(5%) with minimal sun exposure (p<0.0001). No significant relationship was found between severe 
VTD deficiency and season, doctor affiliation, or fish consumption. Although no significant 
relationship between BMI and severe deficiency was found, 12% of underweight individuals were 
severely deficient compared to 2-4% in other BMI categories. 
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Table 6. Severe Vitamin D Deficiency by Demographic and Lifestyle Characteristic. 
 
 
 
Characteristic 
 25(OH)D Level – n (%) 
P-value 
<25 nmol/L  ≥ 25 nmol/L 
Age     0.1656 
   Pediatric (<19 years)  4 (5%)  83 (95%)   
   Young Adult (19-29 years)  8 (5%)  164 (95%)   
   Middle Adult (30-59 years)  28 (4%)  726 (96%)   
   Senior (60+ years)  8 (2%)  412 (98%)   
Sex     0.4022 
   Male  15 (4%)  355 (96%)   
   Female  33 (3%)  1030 (97%)   
Skin Tone      <0.0001 
   Dark  4 (22%)  14 (78%)   
   Midcolor  13 (7%)  172 (93%)   
   Light  25 (2%)  1154 (98%)   
   First Nations  6 (18%)  27 (82%)   
Pregnant (Females Only)      0.3198 
   No  29 (3%)  948 (97%)   
   Yes  4 (5%)  79 (95%)   
BMI (n=704)      0.0730 
   Underweight  4 (12%)  29 (88%)   
   Normal  9 (3%)  313 (97%)   
   Overweight  8 (4%)  209 (96%)   
   Obese  3 (2%)  129 (98%)   
Fish Oil Supplement      0.0004 
   No  46 (4%)  1028 (96%)   
   Yes  2 (1%)  335 (99%)   
Vitamin D Supplement      <0.0001 
   None  45 (6%)  669 (94%)   
   50-400 IU  2 (0.4%)  485 (99.6%)   
   >400 IU  1 (0.5%)  209 (99.5%)   
Glasses of Milk per day      0.0001 
   None  38 (5%)  675 (95%)   
   1-2  9 (2%)  483 (98%)   
   >2  1 (0.5%)  205 (99.5%)   
Recent Sun Exposure     <0.0001 
   Minimal  46 (5%)  832 (95%)   
   Moderate  1 (0.3%)  361 (99.7%)   
   Lots of Sun  1 (0.6%)  170 (99.4%)   
Overall    48 (3%)  1385 (97%)   Int. J. Environ. Res. Public Health 2009, 6          
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4. Discussion 
 
The findings of this study are consistent with results from other VTD research suggesting the reality 
of a hypovitaminosis-D pandemic in some population groups residing at higher latitudes. Although a 
limitation of this research is selection bias in the overall sample – as all three physicians have a 
particular interest in clinical nutrition with a large percentage of MDB’s sample, for example, already 
using fish oil supplements – the likely reality is that VTD levels in the general population may be even 
lower than those expressed in the overall sample and may more closely approximate MDA’s sample of 
newly referred patients. As the sample in each clinical practice is not randomized and represents a 
sample of convenience, however, it is not possible to conclude from the data that VTD levels in this 
study are representative of the general population. Within each practice and the overall sample, 
nonetheless, it is relevant to consider associations between various demographic and lifestyle factors 
with VTD status.  
Recognized reasons for inadequate VTD status include a) insufficient skin synthesis [1]; b) 
inadequate ingestion; and c) impaired renal synthesis of 1,25-dihydroxyvitamin D resulting from 
accumulated toxicants such as lead, aluminum and cadmium [55]. It is unknown to what degree 
toxicant accretion in selected populations such as Aboriginal groups with specific habitat location, 
lifestyle and dietary practices contributes to VTD related pathology, but recent Centers for Disease 
Control findings of widespread toxicant stockpiling including heavy metals [56] suggest that further 
exploration of this issue may be indicated. 
The results of this research study are consistent with numerous other studies in that selected 
lifestyle and demographic characteristics such as supplementation, skin tone, diet, and sun exposure 
have a profound impact on VTD status; these findings are not an epiphany. For example, various other 
studies have reported high rates of VTD deficiency in First Nations communities [44-48], where 
rickets and osteomalacia appear to be rising [57]. To summarize the findings from this study in 
conjunction with numerous reports and reviews in the medical literature: i) there is a widespread 
problem of inadequate VTD status in certain population groups particularly those residing at higher 
latitudes; ii) there has been a clear association between specific demographic factors and VTD status; 
and iii) innumerable studies confirm the benefits of VTD adequacy in individuals and population 
groups. Despite the plethora of studies and generally consistent outcomes, however, the widespread 
problem of hypovitaminosis-D persists. The focus of this discussion, therefore, will be on 
considerations and strategies related to the desired effect of this study - the application of these results 
to clinical practice and public health. 
 
Application of Vitamin D Research to Clinical Practice and Public Health 
 
As well as the existence of widespread VTD inadequacy and ample understanding of causative 
determinants, emerging research confirms two important observations related to VTD epidemiology. 
First, there is a plethora of evidence linking adverse health outcomes to hypovitaminosis-D, a 
particular problem in higher latitudes. Most people produce VTD in response to UVB exposure from 
the sun - as ozone blocks UVB emission, the rays become progressively less intense at higher latitudes Int. J. Environ. Res. Public Health 2009, 6          
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where sunlight has an increasing angle of penetration and travels greater distances through the earth’s 
atmosphere. The net result is diminished VTD production at higher latitudes, particularly during winter 
months. Michael Holick, a pioneer in the unfolding VTD story, noted in a recent review paper that 
living at higher latitudes is associated with an increased risk for developing type 1 diabetes, multiple 
sclerosis, Crohn’s disease, hypertension, cardiovascular disease, Hodgkin’s lymphoma, and myriad 
cancers including colon, pancreas, prostate, ovarian, and breast [1] – residents of higher latitudes are 
also more likely to die from these cancers [1].  
Secondly, there is general acknowledgment that simple and low-cost measures have the potential to 
address the problem of VTD inadequacy. VTD can be obtained from: a) food sources such as fatty fish 
and fortified foods; b) skin exposure to UVB light from sun or artificial light sources; and c) VTD 
supplementation. For those unable to obtain adequate sunlight and/or VTD replete or fortified foods, 
VTD is readily accessible through low-cost supplementation. Regardless of ample epidemiological 
data confirming hypovitaminosis-D in many population groups, however, there remains a profound 
lethargy in moving from data dialogue to actual implementation of clinical measures to address this 
serious public health problem. Despite abundant evidence and available solutions, primary care 
practitioners are not yet at a place where VTD assessment and intervention is the standard of care. 
What accounts for this lethargy and how can medical progress be facilitated? 
a) Professional Lethargy 
Knowledge translation is a description of the process whereby evidence from emerging research is 
adopted into clinical practice [58]. The stark reality in medicine is that, no matter the evidence, there 
is sometimes serious difficulty translating knowledge from emerging research into day-to-day clinical 
implementation. [59, 60] Medical history is replete with examples where sluggish dissemination and 
adoption of innovation has extracted a heavy toll. It was not until his contemporaries died and a new 
generation of physicians emerged that Semmelweis’ hand washing intervention to prevent 
transmission of organisms and puerperal sepsis was implemented [61]. It took more than 40 years 
before Lind’s recommendation to eat citrus as the solution to scurvy took hold [59]. More recently, 
Nobel Prize recipient Barry Marshall, reflecting on the length of time necessary to incorporate research 
about H. Pylori in ulcer management remarked, “Was gastroenterology a science or a religion? I
 
decided it was the latter [62].” 
With understandable reluctance to embrace new fads, the medical community is sometimes slow to 
adopt scientific findings when research lacks industry funding and the associated marketing prowess. 
Reasons to account for the lethargy in knowledge translation include: a) there is circa six million 
medical articles produced annually and more than 10 000 new randomized trials indexed on Medline 
each year [63] – it is unrealistic for busy clinicians to be sufficiently apprised of all recent information; 
b) with non-commercial endeavors, impetus and funding for dissemination of new findings may not be 
available; and c) typical human behavior includes a reticence to change, particularly if novel 
information threatens the credibility or support of existing beliefs. This tardiness, however, is in 
contrast to incorporation of preliminary or suggestive findings supported by industry such as was seen 
with hormone replacement therapy [64] and some other pharmaceuticals including certain COX-2 
inhibitors – where recent concerns about lack of adequate study and adverse outcomes suggest that Int. J. Environ. Res. Public Health 2009, 6          
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incorporation into clinical practice may, at times, be too hasty [65]. With no major commercial 
sponsor, the move to implement VTD assessment and management into widespread clinical practice 
has not been readily embraced.  
b) Solar Abstinence 
Exposure to UVB rays from sunlight has traditionally been the greatest source of VTD for most 
individuals. Based on the presupposition that sun exposure causes skin cancer, a cultural mindset has 
evolved over the last few decades that sun exposure is unhealthy and solar abstinence is preferable. 
With widespread use of sunblock and adherence to pervasive admonitions to ‘cover up’, much of the 
western world has endeavored to avoid solar rays. Although sunburn is recognized to be injurious, 
recent research has challenged the fallacy that judicious sun exposure is harmful and suggests that 
sensible and regular doses of sunlight are necessary for health and well being [66, 67]. In fact, prudent 
exposure to sunlight results in VTD production and appears to have a protective influence on various 
cancers [68]. Furthermore, evidence continues to accumulate that other physiological processes 
including endogenous serotonin production may also be dependent on direct sun exposure [69].  
Widespread use of topical sunblock which significantly reduces VTD skin production, and the 
increasing trend to remain indoors have contributed to the hypovitaminosis-D pandemic. The sun-
phobic mentality needs to be revisited and the medical community should be at the forefront of 
addressing this pervasive cultural construct. 
c) Educational Deficiency 
Within a medical paradigm of avant-garde robotic surgical procedures and futuristic epigenomic 
medical research, clinical nutrition is often perceived as simplistic medicine and not within the routine 
realm of cutting-edge medical professionals. With the misguided notion that populations in western 
countries are receiving all the nutrients they require from diet, expertise in clinical nutrition is not 
secured in most medical schools [3] and proficiency in clinical nutrition is often relegated to non-
physician groups. Increasing research continues to elucidate, however, that common deficiencies in 
essential nutrients such as VTD and essential fatty acids [70, 71] are contributing to widespread illness 
and that current recommended intake values of some nutrients including VTD have not incorporated 
recent research.  
A major determinant in the clinical adoption of new information, however, is the compatibility of 
research findings with existing beliefs and values – people feel most comfortable when new 
information fits within the framework of what they know. Correspondingly, many are inclined to 
ignore or dismiss emerging science, no matter how credible, if findings challenge their cerebral 
paradigm. Citrus fruit to cure scurvy, for example, and living organisms as the cause of puerperal fever 
were a tough sell in a medical climate captivated with Galen’s theory of inherited ‘humours’ as the 
etiology of illness [72]. Ironically, Eijkman’s subsequent discovery of nutrient deficiency as the cause 
of beriberi was initially rejected [73] as it did not fit into a medical paradigm that had swung to 
embrace Semmelweis’ teaching on living organisms [61], and Pasteur’s ‘germ theory’ [74] as the 
predominant cause of disease. In our current medical paradigm, widespread VTD deficiency as a major Int. J. Environ. Res. Public Health 2009, 6          
 
164
determinant of infirmity also remains a tough sell in a medical culture where the mindset of ‘genetic 
predestination’ [75] as the source of most illness rules the day and nutritional interventions continue to 
be perceived as ‘complementary’ or ‘alternative’ medicine. 
Just as architects or building engineers need to understand intricate details of building materials to 
address difficulties within structures, clinicians need to comprehensively understand how to investigate 
and manage the status of nutrients - the prerequisite materials of human physiology and repair [2]. 
With the increasing attribution of much illness to nutritional compromise [76] and rising attention to 
emerging areas such as nutrigenomics and nutritional epigenetic determinants of illness, it is time to 
revisit science-based education on clinical nutrition at all levels of medical education. 
d) Quo Vadis 
As discussed, the emerging literature in the fields of information science and knowledge translation 
suggest that diffusion of innovation in medicine tends to be slow. As a result, many patients continue 
to be denied credible and effective interventions while some continue to receive ineffective therapies. 
For example, recent study suggests that up to 25% of patients receive treatments deemed to be useless 
or harmful [63], while up to 40-50% fail to receive evidence-based interventions or therapies in 
keeping with current scientific evidence [63, 77]. In order to facilitate the process of knowledge 
translation to achieve widespread VTD sufficiency in individuals and population groups, discussion of 
the process of change is in order. 
The interplay and interdependence of various determinants which govern uptake of research 
evidence into clinical practice have recently been explored [63, 78-80] – essential knowledge that is 
effectively utilized by industry. Successful knowledge translation and clinical implementation requires 
three fundamental steps: 1) Evidence confirming need for change; 2) Change placed in context of 
users; and 3) Facilitation of change implementation [80]. To fulfill these requirements in an effort to 
diminish morbidity and mortality related to VTD inadequacy, interventions utilizing knowledge 
translation research are presented for consideration. 
Many studies confirm the existence of widespread hypovitaminosis-D and the potential health 
sequelae [81]; the need for change is evident. To position any proposed clinical innovation within the 
context of physician activity requires understanding of typical physician behavior. Change in clinical 
practice patterns is much more a function of source of information rather than content; clinical minds 
are most effectively impacted by people and relationships, not research and data [78, 79]. Physicians 
generally change their practice behavior not in direct response to research evidence in journals but in 
response to what they perceive their colleagues are doing (the standard of care) [78, 79] – often 
communicated at impressive educational events by ostensibly credible experts called ‘opinion leaders’ 
or ‘thought leaders’. Such presentations are designed to communicate a proposal for change that 
appears evidence-based, feasible, and attractive to attendees.  
It might be effectual to organize similar events, where dissemination of recommended directives to 
regularly secure VTD sufficiency in patients (not unlike performing regular pap smears in women) is 
advanced to clinicians. Clear instruction on the ease of laboratory screening, interpretation, and 
intervention for VTD-related issues would facilitate change implementation by making transition 
practical and effective. Communicating to health practitioners that no complexity of decision-making Int. J. Environ. Res. Public Health 2009, 6          
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is required, that no new skills must be acquired, and that no organizational change is necessary may 
assist the rapidity of adoption of widespread VTD interventions. Discussion of potential rewarding 
outcomes for patients associated with VTD sufficiency may further enhance knowledge translation.  
From a public health perspective, broad-based education with direct appeal to end users has 
additional potential to address widespread hypovitaminosis-D. Industry has effectively used direct-to-
consumer advertising to achieve commercial success – a technique which has been successful in 
emerging endeavors not tied to industry. A program entitled “Do Bugs Need Drugs”, for example, was 
piloted in one Albertan community to diminish misuse of antibiotics. With recognition that children 
can be bio-vectors of information to families and thus to society at large, university students were 
employed to teach primary school students about appropriate antimicrobial use. With simple 
instruction about queries to pose when doctors recommend antibiotics as well as information for 
parents about management of viral infections, antibiotic use precipitously dropped immediately. 
Similarly, a public awareness campaign and an educational initiative about VTD sufficiency might 
engender an expectation of clinical care related to VTD assessment as well as facilitating the 
widespread acquisition of VTD-related knowledge in society.  
By establishing a standard of care, Clinical Practice Guidelines (CPGs) have proven to be one of the 
most effective tools for facilitating clinical change and potentially improving the quality of care [82] - 
a phenomenon not missed by industry [83]. Development of credible CPGs which delineate 
expectations of VTD assessment and management may help establish a standard of VTD care and may 
be instrumental in facilitating change. Additional public health measures might include a consensus 
statement on sun exposure, updated VTD intake recommendations, and increasing food fortification. 
Finally, it would seem prudent that medical regulatory bodies - anointed with the mandate of securing 
and preserving the public interest - ensure that health professionals under their watch are apprised of 
important but oft ignored medical interventions. 
e) Recommended Dosing 
Suggested VTD supplemental intake levels are currently being discussed by various groups. 
Although variation may exist, available evidence suggests that 40 IU of daily VTD supplementation 
will raise serum 25(OH)D by about 1 nmol/L (range 0.7–2.0 nmol/L) [84-86]. As supplemental VTD 
intake of 1,000 IU generally increases 25(OH)D levels by about 25 nmol/l, additional daily intake of 
2,000 IU VTD for individuals in this study would eliminate deficiency and elevate VTD status to 
adequate levels in most. (Table 7) With superior pre-existing levels in participants with high sun 
exposure and tanning bed use (Table 5), caution should be exercised to avoid reaching levels 
considered potentially toxic (>250 nmol/l). In reality, however, toxicity at daily supplemental doses of 
2,000 IU for individuals at high latitudes are unlikely as daily doses of 10,000 IU for up to 5 months 
have failed to cause toxicity [84,87]. In fact, mean 25(OH)D values observed after 20 weeks of 10,000 
IU/d VTD supplementation during winter months for individuals at higher latitudes are in the range of 
220 nmol/L [87]. To secure healthy VTD values and to assure avoidance of toxicity, measurement of 
25(OH)D levels when indicated is available to help direct clinical care. 
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Table 7. Projected Vitamin D Status with Daily VTD Supplementation*. 
Category 
25(OH)D Level – n (%)  25(OH)D Level (nmol/L) 
<40 nmol/L  40 to <80 nmol/L  80-250 nmol/L  >250 nmol/L  Mean  SD 
Current  240 (16.75%)  738 (51.5%)  455 (31.75%)  0 (0%)  68.33  28.95 
Current plus 
1,000 IU
a 
8 (1%)  477 (33%)  948 (66%)  0 (0%)  93.33  28.95 
Current plus 
2,000 IU
b 
0 (0%)  100 (7%)  1,332 (93%)  1** (<1%)  118.33  28.95 
 
a   Current plus 1,000 IU is the case where every participant takes an additional 1,000 IU/d VTD 
b  Current plus 2,000 IU is the case where every participant takes an additional 2,000 IU/d VTD 
* Projections based on available evidence that 40 IU/d of VTD supplementation will raise serum 
25(OH)D by about 1 nmol/L [84-86]. 
** One individual’s projected levels went above 250 nmol/L with supplementation. This individual 
had high sun exposure, regular tanning bed usage, and no supplementation. 
f) Potential Health and Economic Outcomes 
The potential magnitude of outcome resulting from interventions to address the pandemic of low 
VTD can be realized by considering an important epidemiological concept entitled ‘number needed to 
treat’ (NNT). The NNT, a calculation discussed in a 1988 publication of the New England Journal of 
Medicine [88], refers to the number of patients who need to be treated with a given intervention in 
order to prevent one additional bad outcome. The NNT is a valuable measure of the practical 
usefulness of a health care intervention – a measure which incorporates both the incidence of the 
adverse condition and the effectiveness of the intervention.  
For example, a study was recently undertaken to investigate the efficacy in prevention of coronary 
and stroke events of the most widely used lipid-lowering agent in the world - atorvastatin (Lipitor) - in 
patients with hypertension but without previous cardiovascular disease or dyslipidemia [89]. Lipid-
lowering therapies are the best-selling medicines in history, used by more than 25 million patients 
throughout the globe, producing $27.8 billion in sales in 2006 – about half of which are associated 
with atorvastatin. In this clinical trial, 10,305 hypertensive patients were randomly assigned 
atorvastatin 10 mg or placebo [89]. The clinical trial ran for 3.3 years and after statistical analysis was 
completed, it was determined that the NNT was 99.7 – that is, close to 100 patients with this clinical 
scenario would require ongoing treatment for 3.3 years in order to prevent just one cardiovascular 
event. The study interpretation concluded that “the reductions in major cardiovascular events with 
atorvastatin are large [89].” 
The impact of VTD therapy, however, may be a great deal more significant - as the benefits of VTD 
sufficiency, according to recent scientific literature, appear to affect a plethora of common conditions 
in addition to cardiovascular events. (Table 1) If we consider the high incidence of specific diseases 
associated, in some cases, with VTD inadequacy (including breast, colon, pancreatic and prostate 
cancer; cardiovascular events, congestive heart failure, hypertension and fatal stroke; assorted 
musculoskeletal problems; upper and lower respiratory infections; various autoimmune conditions 
including multiple sclerosis and rheumatoid arthritis; type 1 and type II diabetes; several obstetrical Int. J. Environ. Res. Public Health 2009, 6          
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and gynecological difficulties; etc.), juxtaposed with significant risk reductions for many of these 
illnesses associated with securing VTD sufficiency (Table 1), the evidence is highly suggestive that the 
NNT to derive noteworthy benefit is very low. Accordingly, routine VTD assessment and management 
of all individuals presenting for clinical care would yield positive health outcomes in a high proportion 
of patients. Appropriate VTD care would also relieve the annual economic burden related to VTD 
inadequacy, which was estimated at $40-$56 billion in America alone in 2004 [90]. It is hard to 
envisage another science-based opportunity within contemporary medicine that requires such a simple 
intervention to yield such a huge reward at such low cost and minimal risk. 
 
5. Conclusions 
 
As a consequence of VTD inadequacy, there is a notable gulf between health as it is, and health as it 
could be for many individuals and population groups. Exposure to UVB rays from sunlight is the 
single greatest source of VTD for most individuals, yet for periods of the year UVB intensity is too 
weak at some latitudes to induce sufficient VTD skin synthesis for many people. The findings reported 
in this paper raise concern that in regions of higher latitudes such as Western Canada where UVB 
production is impaired for winter months, widespread VTD deficiency may be present. Furthermore, in 
line with existing research, the study found that individual VTD levels correlate with various 
determinants including nutritional supplementation, skin tone, sun exposure, use of tanning beds, fish 
ingestion and medical practice patterns. Underweight individuals as well as participants with First 
Nations and dark skin tone appear to be at particular risk for severe deficiency. 
As VTD is well recognized to have genomic activity and to influence numerous cell processes, 
VTD inadequacy has been correlated with myriad health problems including various cancers, 
compromised bone health, all-cause mortality, autoimmune dysfunction, cardiovascular disease, 
respiratory affliction, as well as obstetrical and gynecological pathology. Furthermore, as 
hypovitaminosis-D is easily identified and corrected, the medical community has an enormous 
opportunity as well as an ethical imperative to improve individual and public health by advancing 
measures - including regular VTD supplementation when required - designed to secure VTD adequacy 
in individuals and populations. There is a huge gap, however, between what we know works and what 
is actually done - a phenomenon which poses serious threat to the health and well being of individuals 
and population groups [77]. 
History suggests that the transition from best evidence to best practice can be arduous [63]. Many 
patients receive inappropriate or detrimental care because innovation in clinical medicine often 
proceeds too slowly, despite abundant evidence. If historical precedent persists, emerging VTD 
information will not be incorporated into clinical practice for years to come. Using research from the 
fields of information science and knowledge translation, discussion about impediments to 
advancement in VTD care is presented for consideration along with tangible recommendations 
including suggested VTD supplemental intake levels to facilitate medical progress. 
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Key Points 
 
•  Vitamin D inadequacy is very common in populations living at higher latitudes. 
•  Low vitamin D status has been correlated with myriad health problems and increased all-cause 
mortality. 
•  Main determinants of vitamin D status include amount of sun exposure, skin tone, supplemental 
intake, use of tanning beds and fish consumption. 
•  Supplemental intake of 2,000 IU per day for patients living at higher latitudes may be successful at 
normalizing vitamin D status for most people. 
•  Achieving optimal vitamin D levels in the general population may have a significant public health 
impact by effecting diminished morbidity and mortality. 
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